本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Evommune

10.43
-0.1100-1.04%
成交量:35.02萬
成交額:365.31萬
市值:3.79億
市盈率:-4.00
高:10.63
開:10.49
低:10.31
收:10.54
52周最高:33.20
52周最低:10.30
股本:3,629.21萬
流通股本:1,998.20萬
量比:0.27
換手率:1.75%
股息:- -
股息率:- -
每股收益(TTM):-2.6090
每股收益(LYR):-11.2228
淨資產收益率:-52.11%
總資產收益率:-31.99%
市淨率:1.36
市盈率(LYR):-0.93

資料載入中...

公司資料

公司名字:
Evommune
交易所:
NYSE
成立時間:
2020
員工人數:
48
公司地址:
1891 Page Mill Road,Palo Alto,California,United States
郵編:
94304
傳真:
- -
簡介:
Evommune, Inc.是一家於2020年4月在特拉華州註冊成立的公司,總部位於加利福尼亞州的帕洛阿爾托。該公司是一家臨床階段的生物技術公司,專註於針對慢性炎症疾病主要致病因素的創新治療方案開發。其初步臨床開發項目集中在慢性自發性蕁麻疹、特應性皮炎和潰瘍性結腸炎上。

董事

名稱
職位
Benjamin F. McGraw, III
Chairman of the Board and Director
Luis Peña
President,Chief Executive Officer and Director
Eugene A. Bauer
Chief Medical Officer and Director
Arthur Kirsch
Director
David E. Cohen
Director
Derek DiRocco
Director
Felice Verduyn van Weegen
Director
Francois Beaubien
Director
Robert Hopfner
Director
Yuexin Yu
Director

股東

名稱
職位
Luis Peña
President,Chief Executive Officer and Director
Kyle Carver
Chief Financial Officer
Eugene A. Bauer
Chief Medical Officer and Director
Gregory S. Moss
Chief Business and Legal Officer, Corporate Secretary and Chief Compliance Officer
Janice Drew
Executive Vice President,Operations
Jeegar Patel
Chief Scientific Officer